Browsing publications by Dr James Allan

Newcastle AuthorsTitleYearFull text
Dr James Allan
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis2015
Dr Nicola Sunter
Dr Helen Marr
Professor Andy Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk2015
Dr Sarah Fordham
Mike Cole
Dr Julie Irving
Dr James Allan
Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia2015
Dr Julie Irving
Elizabeth Matheson
Helen Blair
Marian Case
Isabella Swidenbank
et al.
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-34302015
Dr Victoria Forster
Mohammed Nahari
Dr Natalia Martinez Soria
Amy Bradburn
Dr Sarah Fordham
et al.
The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype2015
Dr Mark Wade
Dr Nicola Sunter
Dr Sarah Fordham
Anna Long
Dino Masic
et al.
c-MYC is a radiosensitive locus in human breast cells2014
Dr Nicola Sunter
Professor Andy Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Dr James Allan
et al.
A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia2014
Dr Sarah Fordham
Mike Cole
Dr Julie Irving
Dr James Allan
Cytarabine leaves a mutational fingerprint in relapsing leukemia2014
Dr James Allan
Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy2014
Dr James Allan
Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease2014
1234567